Skip to main content

View full-text article in PMC

. 2017 Nov;13(11):651–658.

Table 2.

Postoperative Preventive Strategies

Prophylactic Strategy	Study Design	Comparison	Endoscopic Recurrence	Clinical Recurrence
Mesalamine
Caprilli et al³⁶	Randomized, controlled trial	Mesalazine 2.4 g/d or placebo	52.0% vs 85.0% (24 months)^a	18.0% vs 41.0% (24 months)^a
McLeod et al³⁷	Randomized, controlled trial	Mesalamine 3.0 g/d or placebo	Relative risk, 0.654 (24 months)^a	31.0% vs 41.0% (72 months)^a
Lochs et al³⁹	Randomized, controlled trial	Mesalamine 4.0 g/d or placebo	66.0% vs 50.0% (18 months)	24.5% vs 31.4% (18 months)
Antibiotic
Rutgeerts et al⁴³	Randomized, controlled trial	Metronidazole 20.0 mg/kg or placebo	52.0% vs 75.0% (12 weeks)	4.0% vs 25.0% (12 months)^a
Rutgeerts et al⁴⁴	Randomized, controlled trial	Ornidazole 1.0 g/d or placebo	53.6% vs 78.8% (12 months)^a	7.9% vs 37.5% (12 months)^a
Immunomodulator
Reinisch et al⁴⁷	Randomized, controlled trial	Mesalazine 4.0 g/d or AZA 2.0-2.5 mg/kg/d	N/A	0.0% vs 10.8% (12 months)^a
Hanauer et al⁴⁸	Randomized, controlled trial	6-MP 50 mg or placebo	43.0% vs 64.0% (24 months)^a	50.0% vs 77.0% (24 months)^a
Mowat et al⁴⁹	Randomized, controlled trial	6-MP 1.0 mg/kg or placebo	43.0% vs 49.0% (36 months)	27.0% vs 36.0% (36 months)
Biologic agent
Regueiro et al³³	Randomized, controlled trial	Infliximab 5.0 mg/kg or placebo	9.1% vs 84.6% (12 months)^a	0.0% vs 38.5% (12 months)^a
Regueiro et al⁵⁶	Randomized, controlled trial	Infliximab 5.0 mg/kg or placebo	30.6% vs 60.0% (76 weeks)^a	12.9% vs 20.0% (76 weeks)
De Cruz et al⁵²	Nonrandomized subgroup analysis	Adalimumab or AZA 2.0 mg/kg/d (6-MP 1.5 mg/kg/d)	21.0% vs 45.0% (6 months)^a	18.0% vs 22.0% (6 months)

6-MP, 6-mercaptopurine; AZA, azathioprine; d, day.

^a

Statistically significant.